Enable job alerts via email!
Boost your interview chances
Create a job specific, tailored resume for higher success rate.
A leading company in oncology research is seeking a Director, Clinical Operations EU & Partner Liaison to oversee Phase 3 trials in collaboration with a Chinese partner. This role requires extensive experience in clinical operations, fluency in Mandarin, and strong project management skills to ensure successful trial execution.
Join to apply for the Director, Clinical Operations EU & Partner Liaison role at Summit Therapeutics, Inc.
Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining immunotherapy via PD-1 blockade with anti-angiogenesis effects by blocking VEGF. It displays unique cooperative binding with higher affinity when both targets are present. Summit has initiated clinical development in non-small cell lung cancer (NSCLC), with three active Phase III trials:
Ivonescimab is investigational, not yet approved in the US or Europe, but approved in China as of May 2024. It has received Fast Track designation from the FDA for the HARMONi trials.
We seek a highly qualified Director, Clinical Operations EU & Partner Liaison to oversee Phase 3 global oncology trials in collaboration with our Chinese partner. This role will be the primary contact for clinical operations in China, working closely with the partner. The candidate should have extensive experience in Phase 3 trials, excellent communication skills in Mandarin and English, and the ability to manage cross-cultural and cross-border collaborations.